CLINICAL_TRIALS
trial_result
· 2025-09-12
Clinical Trial Update: Olaparib in Recurrent IDH-mutant Glioma [Phase 2]
Summary
Phase 2 trial of olaparib in recurrent IDH-mutant glioma has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hospices Civils de Lyon | Conditions: Recurrent IDH, Mutant High Grade Glioma | Phase 2 | Status: COMPLETED